BioWorld-International-2009-06-17
Pharnext, Ipsen in $126M Deal for Neuromuscular Compound
Pharnext, Ipsen in $126M Deal for Neuromuscular Compound
Drug repositioning specialist Pharnext out-licensed its lead program in the chronic neuromuscular disease, Charcot-Marie-Tooth, to Ipsen SA in a deal with a value of at least 91 million ($US126.1 million). (BioWorld International)

